BioPharmSignal logoBioPharmSignal

Biotech News

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

Inhibikase Therapeutics (IKT)Inhibikase TherapeuticsEarnings

IKT (IKT) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ikt.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

DNLIDenali Therapeutics2026-08-06 20:01 EST

Denali Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

GERNGeron2026-08-05 11:00 EST

Geron Corporation Reports Second Quarter 2026 Financial Results and Recent Business Highlights

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

KYMRKymera2026-08-05 11:00 EST

Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

View all latest news

Inhibikase Therapeutics

Pulmonary Hypertension Company Inhibikase Therapeutics develops IKT-001 for pulmonary arterial hypertension. IKT-001 The candidate is a differentiated formulation of imatinib intended to retain pulmonary vascular activity while improving tolerability and long-term usability. IMPROVE-PAH The registrational Phase 3 IMPROVE-PAH study is...

Recent company news

IKTInhibikase Therapeutics2026-07-23 12:00 EST

Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH

IKTInhibikase Therapeutics2026-07-14 12:00 EST

Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility

IKTInhibikase Therapeutics2026-07-02 20:01 EST

Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

IKTInhibikase Therapeutics2026-05-12 20:01 EST

Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity

IKTInhibikase Therapeutics2026-04-07 12:00 EST

Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension

Stock data

Close
2.41 USD
Market cap
224.46M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States